Please login to the form below

Not currently logged in
Email:
Password:

chronic lymphocytic leukaemia

This page shows the latest chronic lymphocytic leukaemia news and features for those working in and with pharma, biotech and healthcare.

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

Eli Lilly’s Loxo Oncology revealed some promising early-stage results for its Bruton’s tyrosine kinase (BTK) inhibitor LOXO-305 in patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic

Latest news

More from news
Approximately 13 fully matching, plus 119 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    3. Novartis’ OMB-157 is a monthly or 12-weekly subcutaneous formulation of the anti-CD20 monoclonal antibody Arzerra (which is indicated as an intravenous infusion for chronic lymphocytic leukaemia) in ... 4. Vadadustat is an inhibitor of

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours. ... are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin

  • Astellas: Ten years young Astellas: Ten years young

    Meanwhile, the company has Levact (bendamustine) for chronic lymphocytic leukaemia, non-Hodgkin's lymphomas and multiple myeloma, giving it broader interests in the area.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    chronic lymphocytic leukaemia and relapsed B-cell ALL. ... The course of MDS is highly variable, and around one-third of patients develop acute myeloid leukaemia (AML).

  • Therapy Watch expands oncology and IBD portfolios

    This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... Therapy Watch CML is part of a wider oncology

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....